Misplaced Pages

Siplizumab: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 22:55, 13 November 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology...← Previous edit Revision as of 08:13, 9 December 2011 edit undoCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacol...Next edit →
Line 1: Line 1:
{{Drugbox {{Drugbox
| Verifiedfields = changed | Verifiedfields = changed
| verifiedrevid = 447733790 | verifiedrevid = 464392011


<!--Monoclonal antibody data--> <!--Monoclonal antibody data-->
Line 29: Line 29:


<!--Identifiers--> <!--Identifiers-->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = NA | ChemSpiderID = NA
| CAS_number_Ref = {{cascite|correct|??}} | CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 288392-69-8 | CAS_number = 288392-69-8
| ATC_prefix = none | ATC_prefix = none

Revision as of 08:13, 9 December 2011

Pharmaceutical compound
Siplizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from rat)
TargetCD2
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
KEGG
  (what is this?)  (verify)

Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.

References

  1. ClinicalTrials.gov
Immunosuppressive drugs / Immunosuppressants (L04)
Intracellular
(initiation)
Antimetabolites
Macrolides/
other IL-2 inhibitors
IMiDs
Intracellular
(reception)
IL-1 receptor antagonists
mTOR
Extracellular
Antibodies
Monoclonal
Serum target
(noncellular)
Cellular
target
Unsorted
Polyclonal
-cept (Fusion)
Unsorted
Monoclonal antibodies for the immune system
Immune system
Human
Mouse
Chimeric
Humanized

Immune activation: Dostarlimab
Other: Ibalizumab

Chimeric + humanized
Interleukin
Human
Humanized
Veterinary
Inflammatory lesions
Mouse


Stub icon

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Siplizumab: Difference between revisions Add topic